EC Number   |
Inhibitors |
Structure |
|---|
   2.7.3.2 | 5-(4-([(benzoylphenyl)amino]carbonyl)phenyl)-2-furoic acid |
35% inhibition, docking energy -49.5 kcal/mol |
   |
| 2.7.3.2 | 5-(4-([(biphenyl-4-ylmethyl)amino]carbony)phenyl)-2-furoic acid |
63% inhibition, docking energy -51.8 kcal/mol |
|
| 2.7.3.2 | 5-(4-benzoylbiphenyl-4-yl)-2-furoic acid |
63% inhibition, docking energy -46.3 kcal/mol |
|
| 2.7.3.2 | 5-(4-[(benzylamino)carbonyl]phenyl)-2-furoic acid |
20% inhibition, docking energy -47.4 kcal/mol |
|
| 2.7.3.2 | 5-(4-[[(benzoylphenyl)amino]carbonyl]phenyl)-2-furoic acid |
- |
|
| 2.7.3.2 | 5-(4-[[(biphenyl-4-ylmethyl)amino]carbony]phenyl)-2-furoic acid |
- |
|
| 2.7.3.2 | 5-[4-[(benzylamino)carbonyl]phenyl]-2-furoic acid |
- |
|
| 2.7.3.2 | acetaminophen |
inhibits creatine kinase in cerebellum and hippocampus, the administration of N-acetylcysteine plus deferoxamine reverses the inhibition of creatine kinase activity |
|
| 2.7.3.2 | Acrylamide |
significantly inactivate screatine kinase and glutathione S-transferase and deplete glutathione. When the dietary constituents, tea polyphenols, resveratrol, and diallyl trisulfide are cotreated with acrylamide, all of them can effectively recover the activities of creatine kinase |
|
| 2.7.3.2 | Acrylamide |
CK-BB is kinetically reversibly inactivated by acrylamide accompanied by the disruption of the hydrophobic surface, complete inhibition at 800 mM |
|
